# HETLIOZ® (tasimelteon) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tasimelteon

> The FDA approved HETLIOZ® (tasimelteon), sponsored by Vanda Pharmaceuticals Inc. (VNDA), on Dec 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | HETLIOZ® (tasimelteon) |
| Codes |  |
| Sponsor | Vanda Pharmaceuticals Inc. (VNDA) https://sec-api.dev/companies/vnda/catalysts |
| Indications | jet lag disorder, delayed sleep-wake phase disorder, Sleep Wake Disorders |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Sep 2022: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: jet lag disorder.
- First seen 2025-02-14, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001628280-25-047317): "In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ® in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-036861): "In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ® in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023448): "In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ® in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023448/vnda-20250331.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ® in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### Dec 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-05-08, last confirmed 2025-07-31.
- SEC Form 10-Q (accession 0001628280-25-036861): "In December 2022, the Company filed patent infringement lawsuits, including Hatch-Waxman Act claims, against each of Teva and Apotex in the U.S. District Court for the District of New Jersey (NJ District Court) asserting that U.S. Patent No. 11,285,129, a method of administration patent that was not litigated in the Delaware District Court cases ('129 Patent), will be infringed by Teva's and Apotex' generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023448): "In December 2022, the Company filed patent infringement lawsuits, including Hatch-Waxman Act claims, against each of Teva and Apotex in the U.S. District Court for the District of New Jersey (NJ District Court) asserting that U.S. Patent No. 11,285,129, a method of administration patent that was not litigated in the Delaware District Court cases ('129 Patent), will be infringed by Teva's and Apotex' generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023448/vnda-20250331.htm

### Jul 2023: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-14, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "In July 2023, the FDA accepted our sNDA for HETLIOZ® in insomnia for filing and set a PDUFA target action date of March 4, 2024 for its decision." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-26-007460): "In July 2023, the FDA accepted our sNDA for HETLIOZ® for insomnia for filing." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In July 2023, the FDA accepted our sNDA for HETLIOZ® in insomnia for filing and set a target action date of March 4, 2024 under the Prescription Drug User Fee Act (PDUFA) for its decision." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In July 2023, the FDA accepted our sNDA for HETLIOZ® for insomnia for filing." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### March 4, 2024: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0001628280-25-005761): "In July 2023, the FDA accepted our sNDA for HETLIOZ® in insomnia for filing and set a target action date of March 4, 2024 under the Prescription Drug User Fee Act (PDUFA) for its decision." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### Dec 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-05-08, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001347178-26-000002): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-053855): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-031667): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828026031667/vnda-20260331.htm
- SEC Form 10-Q (accession 0001628280-25-047317): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-036861): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023448): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex in the Delaware District Court, in each case, asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023448/vnda-20250331.htm

### June 2025: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06701396 (Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT06701396

### Sep 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: Delayed Sleep-Wake Phase Disorder.
- First seen 2026-10-28, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-067886): "•In September 2026, Vanda announced positive topline results from the pivotal Phase III study of HETLIOZ® in adults with Delayed Sleep-Wake Phase Disorder (DSWPD)." https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm
- SEC Form 10-Q (accession 0001347178-26-000002): "•In September 2026, we announced positive topline results from the pivotal Phase III study of HETLIOZ® in adults with Delayed Sleep-Wake Phase Disorder (DSWPD)." https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm

### September 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04652882 (Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT04652882

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04652882 (Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT04652882

Calendar months: [June 2025](https://sec-api.dev/fda-calendar/2025-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tasimelteon.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HETLIOZ® (tasimelteon) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tasimelteon

```bibtex
@misc{secapidev_pdufa_tasimelteon_20261116,
  title        = {HETLIOZ® (tasimelteon) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tasimelteon}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tasimelteon_20261116","title":"HETLIOZ® (tasimelteon) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tasimelteon","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
